2019
DOI: 10.1182/blood-2019-129697
|View full text |Cite
|
Sign up to set email alerts
|

Complementary Transplantation Improved Results of Both Peripheral Blood Stem Cells and Unrelated Cord Blood Transplants in Thalassemia: A Multi-Center Study from China

Abstract: Background: Unrelated cord blood (UCB) transplant (UCBT) is not recommended in patients with thalassemia major (TM) so far. Post-transplant (PT) Cyclophosphamide (PTCy) with long pre-transplant immunosuppression therapy have improved haploidentical peripheral blood (PB) stem cell transplant (haplo-SCT) survival in TM patients but with 2/31 primary rejection. So, we designed a novel dual transplantation of UCBT following haplo-SCTwith PTCy(NF-14-TM-CT protocol). Aim:To improve results of haplo-SC… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 0 publications
1
2
0
Order By: Relevance
“…High MNC of PBSC from relative donors combined with unrelated CB were applied. And PTCY with or without a low dose of ATG rather than a regular dose of ATG in vivo T cell depletion in haplo-HSCT in our study (Li et al, 2019;Xiao et al, 2021). Consistently, a series of studies support CMV infection occurred more frequently in haplo-HSCT due to delayed T-cell reconstitution (Dziedzic et al, 2017;Lin et al, 2019;Yokoyama et al, 2019;Solano et al, 2021;Cho et al, 2021).…”
Section: Discussionsupporting
confidence: 82%
See 1 more Smart Citation
“…High MNC of PBSC from relative donors combined with unrelated CB were applied. And PTCY with or without a low dose of ATG rather than a regular dose of ATG in vivo T cell depletion in haplo-HSCT in our study (Li et al, 2019;Xiao et al, 2021). Consistently, a series of studies support CMV infection occurred more frequently in haplo-HSCT due to delayed T-cell reconstitution (Dziedzic et al, 2017;Lin et al, 2019;Yokoyama et al, 2019;Solano et al, 2021;Cho et al, 2021).…”
Section: Discussionsupporting
confidence: 82%
“…The donor selection and the transplant protocol were administered as previously reported ( Li et al., 2012 ; Li et al., 2019 ; He et al., 2020 ; Xiao et al., 2021 ; Wen et al., 2022 ). In brief, a myeloablative conditioning regimen like busulfan (Bu)/cyclophosphamide (Cy)/fludarabine (Flu) with or without thiotepa (TT) was used for HLA-matched relative or unrelative donor transplant with anti-thymocyte globulin (ATG) as in vivo T cell depletion.…”
Section: Methodsmentioning
confidence: 99%
“…The conditioning regimens were depicted in previous studies [ 14 17 ]. Briefly, the myeloablative conditioning regimens consisted of busulfan/cyclophosphamide/fludarabine with or without thiotepa.…”
Section: Methodsmentioning
confidence: 99%